Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Uwe Platzbecker(National Center for Tumor Diseases), Veronika Pozharskaya(Bristol-Myers Squibb (United States)), Matteo Della Porta(University of Milan), Jake Shortt(The University of Melbourne), Amer M. Zeidan(Yale Cancer Center), Sameer Kalsekar(Bristol-Myers Squibb (India)), Yinzhi Lai(Bristol-Myers Squibb (United States)), Karen L. Keeperman(Bristol-Myers Squibb (United States)), Dimana Miteva(Bristol-Myers Squibb (Switzerland)), Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Pierre Fenaux(Assistance Publique – Hôpitaux de Paris), Barkha Aggarwal(Bristol-Myers Squibb (United States)), Rami S. Komrokji(Moffitt Cancer Center), Shelonitda Rose(Universidad San Carlos), David Valcárcel(Vall d'Hebron Hospital Universitari)
Cited by 4
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963